Shingo Matsumoto
Hokkaido University
231 Papers
988 Citations
Shingo Matsumoto is an academic researcher from Hokkaido University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 37, co-authored 204 publications. Previous affiliations of Shingo Matsumoto include National Institutes of Health & National Institute of Radiological Sciences.
Chat about Author
Papers
Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia.
Shingo Matsumoto,Caicun Zhou,Chih-Hsi Kuo,Kiyotaka Yoh,Terufumi Kato,Kazumi Nishino,Naoki Furuya,Shucai Zhang,Dongmei Lin,Yuchen Han,Chin-Chou Wang,Takaya Ikeda,Yoshitaka Zenke,Koichi Goto +13 more
TL;DR: A large number of oncogenic drivers have been identified in non-small cell lung cancer (NSCLC), and most of them occur in less than 5% of patients, and large-scale genomic sequencing shows clear trends in these drivers.
4
O2-7-4Association between immune-related adverse events and efficacy of nivolumab in advanced non-small cell lung cancer
Yuko Usui,Hibiki Udagawa,Keisuke Kirita,Shigeki Umemura,Shingo Matsumoto,Kiyotaka Yoh,Seiji Niho,Koichi Goto +7 more
TL;DR: To understand the pathogenesis of nivolumab-induced pneumonitis, leading to avoiding its onset and increase in severity, patients with malignant melanoma and non-small cell lung cancer were referred to Tokyo Medical University Hachioji Medical Center.
3
•Journal Article
A study of the minimum number of slices required for quantification of pulmonary emphysema by computed tomography
Yutaka Hitsuda,Yuji Kawasaki,Tadashi Igishi,Kazuhito Yasuda,Kazuhiro Kato,Shingo Matsumoto,Masaki Nakamoto,Kiyoshi Hashimoto,Fujii Y,Miyata M,Takao Sasaki,Eiji Shimizu +11 more
TL;DR: It is concluded that overall emphysema can be quantified by using at least three slices: one each of the upper, middle, and lower lung.
3
P1.03-005 Phase 2 Study of Ceritinib in Patients with ALK+ NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
Hidehito Horinouchi,Makoto Maemondo,Toyoaki Hida,Masayuki Takeda,Katsuyuki Hotta,Fumihiko Hirai,Young Hak Kim,Shingo Matsumoto,Tetsuya Mitsudomi,Takashi Seto,S. Moizumi,Kota Tokushige,Ben Hatano,Makoto Nishio +13 more
3
Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.
Tomoko Shiraishi,Kei Yamasaki,Moe Kidogawa,Tatsuya Shingu,Fuki Ujimiya,Takanobu Jotatsu,Shingo Matsumoto,Hiroki Izumi,Chinatsu Nishida,Koichi Goto,Kazuhiro Yatera +10 more
TL;DR: In this article , the mesenchymal-epithelial transition (MET) gene plays an important role in anticancer drug resistance to anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs).
3